HER-2 expression

P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027

P1/2, N=60, Recruiting, Beijing Biotech

P3, N=1000, Not yet recruiting, The Netherlands Cancer Institute

Moderately high tumor-to-background ratios, along with washout from the other non-target organs, were observed. Inhibition studies revealed 52.6% reduction in the tumor activity, signifying high HER2-receptor specificity of the presently studied radiopeptide, [99mTc]Tc-CGGG-rL-A9.

This study developed CT-based radiomics habitat models for predicting HER2 expression in gastric cancer. Habitat3 achieved optimal performance, and its combination with clinical variables yielded superior efficacy and clinical applicability, providing a robust non-invasive tool for preoperative HER2 assessment in gastric cancer.

We position this regulatory axis within the broader landscape of established resistance mechanisms and emerging therapeutic strategies, including antibody-drug conjugates, kinase inhibitors, and rational combination approaches. By integrating canonical resistance pathways with transcriptional regulation, this review provides a balanced perspective on how downstream regulatory processes may influence therapeutic response in HER2-positive gastric cancer.

Accurate assessment of Human Epidermal Growth Factor Receptor 2 (HER2) immunohistochemistry (IHC) expression, particularly the precise identification of "HER2 ultra-low" status, is critical for guiding antibody-drug conjugate (ADC) therapies, such as trastuzumab deruxtecan (T-DXd) in breast cancer...These findings demonstrate that AI support enhances the accuracy, consistency, and efficiency of HER2 ultra-low identification across biopsy, resection, and post-treatment specimens, potentially improving patient selection for novel ADC therapies. With AI support, pathologists can deliver more precise and confident diagnoses of HER2 ultra-low breast cancer.

P1, N=51, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

P2, N=124, Recruiting, The First Affiliated Hospital with Nanjing Medical University

As an illustrative example, we apply these methods in a pooling analysis to evaluate the association between Human Epidermal Growth Factor Receptor 2 (HER2) gene expression levels and breast cancer risk. The full package is available online at https://github.com/luyiyun/bayesian_biomark_pooling.

P2, N=146, Not yet recruiting, chenxu

Notably, Ebastine promoted macrophage infiltration and M1 polarization both in vivo and in vitro. Our findings establish Ebastine as a promising therapeutic candidate for EGFR/ERBB2-mutant lung adenocarcinoma through a unique dual-targeting approach that combines direct tumor cell inhibition with enhancement of anti-tumor immunity.